glp 1 drugs anti inflammatory 2024 Multiple Sclerosis Highlight The expanding benefits of GLP-1

Choosing a trusted provider is crucial

These drugs fall within two categories: human GLP-1 backbone agents (that is, albiglutide, dulaglutide, liraglutide and semaglutide) and exendin-4 backbone agents (that is, exenatide, lixisenatide and tirzepatidethe latter activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors) 1

doi: 10.1111/dom.15083

10.1007/s12325-009-0014-9 182 TanX.HuJ

Acknowledgments These studies were supported by NIH (NIDDK): DK-54016 (PKD), DK-81858 (PKD), DK-92441 (PKD), DK96254 (SS) Department of Veterans Affairs Merit Award BX002011 (PKD), TUBITAK AWARD (HO)

With the effects seen of the GLP-1 family of drugs on preventing kidney damage in diabetes, liver disease (non-alcoholic or metabolic-associated steatosis, NASH/MASH), and addiction, this drug class is exceeding all expectations